167 related articles for article (PubMed ID: 34457284)
1. Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review.
Gatto L; Franceschi E; Tosoni A; Di Nunno V; Maggio I; Tonon C; Lodi R; Agati R; Bartolini S; Brandes AA
Clin Case Rep; 2021 Aug; 9(8):e04604. PubMed ID: 34457284
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse.
Auer TA; Breit HC; Marini F; Renovanz M; Ringel F; Sommer CJ; Brockmann MA; Tanyildizi Y
J Neuroradiol; 2019 Feb; 46(1):36-43. PubMed ID: 29733920
[TBL] [Abstract][Full Text] [Related]
3. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.
Gállego Pérez-Larraya J; Lahutte M; Petrirena G; Reyes-Botero G; González-Aguilar A; Houillier C; Guillevin R; Sanson M; Hoang-Xuan K; Delattre JY
Neuro Oncol; 2012 May; 14(5):667-73. PubMed ID: 22492961
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
Gahrmann R; van den Bent M; van der Holt B; Vernhout RM; Taal W; Vos M; de Groot JC; Beerepoot LV; Buter J; Flach ZH; Hanse M; Jasperse B; Smits M
Neuro Oncol; 2017 Jun; 19(6):853-861. PubMed ID: 28204639
[TBL] [Abstract][Full Text] [Related]
5. PET/MR in recurrent glioblastoma patients treated with regorafenib: [
Lombardi G; Spimpolo A; Berti S; Campi C; Anglani MG; Simeone R; Evangelista L; Causin F; Zorzi G; Gorgoni G; Caccese M; Padovan M; Zagonel V; Cecchin D
Br J Radiol; 2022 Jan; 95(1129):20211018. PubMed ID: 34762492
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib in Glioblastoma Recurrence: How to Deal With MR Imaging Treatments Changes.
Gaudino S; Marziali G; Giordano C; Gigli R; Varcasia G; Magnani F; Chiesa S; Balducci M; Costantini AM; Della Pepa GM; Olivi A; Russo R; Colosimo C
Front Radiol; 2021; 1():790456. PubMed ID: 37492166
[TBL] [Abstract][Full Text] [Related]
7. 68Ga-Prostate-Specific Membrane Antigen-11 PET/CT: A New Imaging Option for Recurrent Glioblastoma Multiforme?
Kunikowska J; Kuliński R; Muylle K; Koziara H; Królicki L
Clin Nucl Med; 2020 Jan; 45(1):11-18. PubMed ID: 31663868
[TBL] [Abstract][Full Text] [Related]
8. Unusual Magnetic Resonance Imaging Findings of a Glioblastoma Arising During Treatment with Lenvatinib for Thyroid Cancer.
Arai N; Sasaki H; Tamura R; Ohara K; Yoshida K
World Neurosurg; 2017 Nov; 107():1047.e9-1047.e15. PubMed ID: 28804045
[TBL] [Abstract][Full Text] [Related]
9. Case 271.
Sun Y; Overby PJ; Mehta H
Radiology; 2019 Jul; 292(1):259-262. PubMed ID: 31219757
[TBL] [Abstract][Full Text] [Related]
10. Pre- and post-contrast three-dimensional double inversion-recovery MRI in human glioblastoma.
Harris RJ; Cloughesy TF; Pope WB; Godinez S; Natsuaki Y; Nghiemphu PL; Meyer H; Paul D; Behbahanian Y; Lai A; Ellingson BM
J Neurooncol; 2013 Apr; 112(2):257-66. PubMed ID: 23344788
[TBL] [Abstract][Full Text] [Related]
11. Dramatic response to regorafenib in early glioblastoma progression: case report and review of the literature.
De Felice M; De Marinis P; Martin G; Bruscella S; De Bellis A; Poliero L; Turitto G
Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5008-5013. PubMed ID: 35916797
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.
Zeiner PS; Kinzig M; Divé I; Maurer GD; Filipski K; Harter PN; Senft C; Bähr O; Hattingen E; Steinbach JP; Sörgel F; Voss M; Steidl E; Ronellenfitsch MW
J Clin Med; 2019 Nov; 8(12):. PubMed ID: 31766326
[TBL] [Abstract][Full Text] [Related]
13. Sulcal hyperintensity on fluid-attenuated inversion recovery imaging in acute ischemic stroke patients treated with intra-arterial thrombolysis: iodinated contrast media as its possible cause and the association with hemorrhagic transformation.
Kim EY; Kim SS; Na DG; Roh HG; Ryoo JW; Kim HK
J Comput Assist Tomogr; 2005; 29(2):264-9. PubMed ID: 15772550
[TBL] [Abstract][Full Text] [Related]
14. Abrogation of fluid suppression in intracranial postcontrast fluid-attenuated inversion recovery magnetic resonance imaging: A clinical and phantom study.
Dickinson PJ; Jones-Woods S; Cissell DD
Vet Radiol Ultrasound; 2018 Jul; 59(4):432-443. PubMed ID: 29424062
[TBL] [Abstract][Full Text] [Related]
15. Targeted magnetic resonance imaging (tMRI) of small changes in the T
Ma YJ; Moazamian D; Port JD; Edjlali M; Pruvo JP; Hacein-Bey L; Hoggard N; Paley MNJ; Menon DK; Bonekamp D; Pravatà E; Garwood M; Danesh-Meyer H; Condron P; Cornfeld DM; Holdsworth SJ; Du J; Bydder GM
Quant Imaging Med Surg; 2023 Oct; 13(10):7304-7337. PubMed ID: 37869282
[TBL] [Abstract][Full Text] [Related]
16. The LUMIERE dataset: Longitudinal Glioblastoma MRI with expert RANO evaluation.
Suter Y; Knecht U; Valenzuela W; Notter M; Hewer E; Schucht P; Wiest R; Reyes M
Sci Data; 2022 Dec; 9(1):768. PubMed ID: 36522344
[TBL] [Abstract][Full Text] [Related]
17. Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria.
Radbruch A; Lutz K; Wiestler B; Bäumer P; Heiland S; Wick W; Bendszus M
Neuro Oncol; 2012 Feb; 14(2):222-9. PubMed ID: 22146386
[TBL] [Abstract][Full Text] [Related]
18. Multiparameter MRI Predictors of Long-Term Survival in Glioblastoma Multiforme.
Stringfield O; Arrington JA; Johnston SK; Rognin NG; Peeri NC; Balagurunathan Y; Jackson PR; Clark-Swanson KR; Swanson KR; Egan KM; Gatenby RA; Raghunand N
Tomography; 2019 Mar; 5(1):135-144. PubMed ID: 30854451
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility and Tumor Size Changes During the Time Course of Standard Treatment in Recurrent Glioblastoma.
van Leyen K; Roelcke U; Gruber P; Remonda L; Berberat J
J Neuroimaging; 2019 Sep; 29(5):645-649. PubMed ID: 31112344
[TBL] [Abstract][Full Text] [Related]
20. The Definition and Delineation of the Target Area of Radiotherapy Based on the Recurrence Pattern of Glioblastoma After Temozolomide Chemoradiotherapy.
Zheng L; Zhou ZR; Yu Q; Shi M; Yang Y; Zhou X; Li C; Wei Q
Front Oncol; 2020; 10():615368. PubMed ID: 33692942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
